<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4087">
  <stage>Registered</stage>
  <submitdate>21/08/2013</submitdate>
  <approvaldate>21/08/2013</approvaldate>
  <nctid>NCT01928459</nctid>
  <trial_identification>
    <studytitle>Phase 1b Trial of BGJ398/BYL719 in Solid Tumors</studytitle>
    <scientifictitle>A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CBGJ398X2102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Solid Tumors</healthcondition>
    <healthcondition>Metastatic Solid Tumors</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BGJ398
Treatment: drugs - BYL719

Experimental: Metastatic breast cancer - Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.

Experimental: Solid tumor arm 1 - Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.

Experimental: Solid tumor arm 2 - Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3

Experimental: Dose escalation - To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.


Treatment: drugs: BGJ398
BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.

Treatment: drugs: BYL719
BYL719 will be administered orally once daily on each day of the 28-day cycle.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence rate of dose limiting toxicities (DLTs) of the combination of BGJ398 with BYL719 - The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or the recommended dose for expansion (RDE). Safety(incidence and nature of DLTs), pharmacokinetic and pharmacodynamic data will guide dose escalation decisioins.</outcome>
      <timepoint>Approximately 8 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability of BGJ398/BYL719 combination at the recommended dose for expansion (RDE) - This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions and reductions</outcome>
      <timepoint>Every 28 days from baseline visit until end of study visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate - Assessment of preliminary antitumor activity of the combination of BGJ398 with BYL719; Overall response rate = complete response + partial response</outcome>
      <timepoint>Every two months from the date of baseline CT scan</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival - Assessment of preliminary antitumor activity of the combination of BGJ398 with BYL719</outcome>
      <timepoint>Every two months from the date of baseline CT scan</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time vs. concentration profile of BGJ398 and BYL719 - Plasma concentration versus time profiles. Plasma PK parameters will be used to characterize the PK profiles of the combination of BGJ398 with BYL719</outcome>
      <timepoint>Every 28 days for up to 10 cycles</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically/cytologically confirmed advanced or metastatic solid tumors who have
             failed standard therapy or for whom no effective standard anti-cancer therapy exists

          -  Documented PIK3CA mutations in all patients in dose escalation and expansion with or
             without documented genetic alterations in FGFR depending upon dose expansion cohort
             (either local or central determination)

          -  Measurable disease defined by RECIST v1.1

          -  ECOG performance status of =2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior PI3Ki or selective FGFR inhibitor treatment (for patients enrolled to expansion
             part)

          -  Colorectal cancer (for patients enrolled to expansion part)

          -  Patients with diabetes mellitus requiring insulin treatment and/or with clinical signs
             or with fasting glucose = 140 mg/dL / 7.8 mmol/L, history of clinically significant
             gestational diabetes mellitus or documented steroid-induced diabetes mellitus

          -  Use of medications that increase serum levels of phosphorus and/or calcium

          -  Inorganic phosphorus outside of normal limits

          -  Total and ionized serum calcium outside of normal limits</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>62</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Herblain cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MI</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>MO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Korea</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bellinzona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose
      tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01928459</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>